Strategic Relationship and Significant Investment in OHG by Prominent Japanese Corporation

Formal Strategic Relationship with Alfresa Corporation:

Exclusive Distribution Agreement in Japan and a Significant Investment in OHG

During the last week of December 2023, One Health Group (OHG) and Alfresa Corporation, a multi-billion-dollar leader in the Japanese healthcare industry, entered into a formal strategic relationship by signing an exclusive agreement with OHG to distribute OHG products in Japan.  They will be marketing OHG’s Voyce solution as part of their animal health & wellbeing offerings. 

Furthermore, on 05 January 2024, through Alfresa’s investment fund partner, Alfresa made a significant investment in OHG’s current seed fundraising round, which is affirmation of their commitment to OHG, and belief in its solution offerings. 


   About OHG

OHG, Inc. is a medical technology innovator with a mission to bring breakthrough health diagnostics, therapeutics, monitoring, screening, and advanced analytics to market.  Driven by seeking solutions to preventing needless animal and human illnesses, often attributable by a lack of health data, OHG has developed a patented mobile health assessment technology that uses intelligent sensors and artificial intelligence to provide personalized, context-based real-time health information.  OHG’s goal is to provide a unique health platform that integrates animal, human, and environmental data, which are intrinsically linked.  For more information, please see: Remote Medical Diagnostics for Animal Health | One Health Group


About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceuticals manufacturing, and operating dispensing pharmacies.  Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥ 2.6 trillion for the fiscal year ended March 31, 2023. For more information, please see:

Share news with others